### **Initial Case Quality Control Form**

Thyroid (THCA)

**Instructions:** This form should be completed for all cases submitted for TCGA, prior to the shipment of samples to the BCR.

Questions regarding this form should be directed to the Tissue Source Site's primary Clinical Outreach Contact at the BCR.

Tissue Source Site (TSS) acknowledges that the Biospecimen Core Resource (BCR) may confirm that the diagnosis of the frozen biospecimen is consistent with the primary diagnosis reported by the TSS through histopathology examination in the BCR laboratory. If the BCR identifies a possible discrepancy, the TSS authorizes the BCR to report these patient results to the TSS by means of a formal report in confidential email format for the quality assurance program of the TSS to address.

| result | results to the TSS by means of a formal report in confidential email format for the quality assurance program of the TSS to address.  |                      |  |                      |                      |                      |                      |                      |              |              |   |   |              |   |
|--------|---|----------------------|--|----------------------|----------------------|----------------------|----------------------|----------------------|--------------|--------------|---|---|--------------|---|
| Tissue | Source Site (TSS):  | TS                   | SS ID:   | TS                   | SS Uniqu             | ıe Patie             | nt ID: _             |                      | _ Interv     | riewer N     | lame: _   |   |              | Interview Date / / /  |
|        | is this TSS received permission from the NCI to provide time intervals as a substitute for requested dates on this form? $\Box$ Yes $\Box$ No lete: Provided time intervals must begin with the date of initial pathologic diagnosis. |                      |  |                      |                      |                      |                      |                      |              |              |   |   |              |   |
| Tumo   | Tumor Information: The following sections are to be provided by a Pathologist.  |                      |  |                      |                      |                      |                      |                      |              |              |   |   |              |   |
| #      | Question  |                      |  |                      |                      |                      | intry Alt            | ernativ              | es           |              |   |   |              | Working Instructions  |
| 1      | Diagnosis   | _                    | Thyroid Papillary Carcinoma  Subtypes  Classical/Usual (Papillary, NOS)  Follicular (99% follicular patterned)  Tall cell (50% tall cell features)  Other, specify |                      |                      |                      |                      |                      |              |              | Indicate the confirmed diagnosis of the tumor submitted for TCGA.  3081934  |   |              |   |
| 2      | Other Diagnosis   |                      |  |                      |                      |                      |                      |                      |              |              |   |   |              | If the diagnosis of the tumor submitted for TCGA is not included in the provided list, specify the diagnosis. 3124492 |
| 3      | Does this specimen have oncocytic variant features?   | □ No                 | □ Yes<br>□ No<br>□ Unknown   |                      |                      |                      |                      |                      |              |              |   | Indicate whether the confirmed diagnosis of the tumor submitted for TCGA contained oncocytic variant features.  3630771 |              |   |
| 4      | Tumor Type  | □ Pri                | ☐ Primary (primary untreated malignant biospecimen)  |                      |                      |                      |                      |                      |              |              | Indicate the type of tumor submitted for TCGA.  328124  This is a biospecimen that has not been treated with chemotherapy (including intravesical treatment) or radiation prior to resection. |   |              |   |
| 5      | Anatomic Organ Sub-<br>Division of Frozen<br>Biospecimen  |                      | ☐ Thyroid, NOS ☐ Thyroid, Left ☐ Thyroid, Isthmus  |                      |                      |                      |                      |                      |              |              |   | Indicate the anatomic site of the frozen tumor biospecimen submitted for TCGA. $\underline{2008006}$                    |              |   |
| 6      | Tumor Focality  |                      | □ Unifocal<br>□ Multifocal*  |                      |                      |                      |                      |                      |              |              | Indicate the focality of the tumor. Include all areas of the tumor. 3174022  *Non-neoplastic control tissue FROM THYROID is exclusionary for multifocal tumor submissions.                    |   |              |   |
| Date   | Date of Cancer Sample Procurement   |                      |  |                      |                      |                      |                      |                      |              |              |   |   |              |   |
| 7      | Month of Cancer Sample<br>Procurement   | <b>□</b> 01          | <b>1</b> 02  | <b>1</b> 03          | <b>1</b> 04          |                      | <b>1</b> 06          | <b>1</b> 07          | □ 08         | <b>1</b> 09  | <b>1</b> 0  | <b>1</b> 1  |              | Provide the month of the procedure performed to obtain the malignant tissue submitted for TCGA.  3008197              |
| 8      | Day of Cancer Sample<br>Procurement   | □ 01<br>□ 13<br>□ 25 | □ 02<br>□ 14<br>□ 26   | □ 03<br>□ 15<br>□ 27 | □ 04<br>□ 16<br>□ 28 | □ 05<br>□ 17<br>□ 29 | □ 06<br>□ 18<br>□ 30 | □ 07<br>□ 19<br>□ 31 | □ 08<br>□ 20 | □ 09<br>□ 21 | □ 10<br>□ 22  | □ 11<br>□ 23  | □ 12<br>□ 24 | Provide the day of the procedure performed to obtain the malignant tissue submitted for TCGA. $\underline{3008195}$   |
| 9      | Year of Cancer Sample<br>Procurement  |                      |  |                      |                      |                      |                      |                      |              |              |   |   |              | Provide the year of the procedure performed to obtain the malignant tissue submitted for TCGA. 3008199                |

| #  | Question   | Entry Alternatives   | Working Instructions   |
|----|--|--|--|
| 10 | Method of Cancer Sample<br>Procurement                           | □ Surgical Resection   | Indicate the procedure performed to obtain the malignant tissue submitted for TCGA. 3103514  |
| 11 | Country Where Cancer<br>Sample was Procured                      |  | Provide the country where the tissue submitted for TCGA was procured. 3203072  |
| 12 | Race   | <ul> <li>□ American Indian or Alaska Native         <ul> <li>A person having origins in any of the original peoples of North and South America (including Central America), and who maintains tribal affiliation or community attachment.</li> <li>□ Asian</li></ul></li></ul>   | Provide the patient's race using the defined categories.  2192199  |
| 13 | Ethnicity  | <ul> <li>Not Hispanic or Latino         <ul> <li>A person not meeting the definition of Hispanic or Latino.</li> </ul> </li> <li>Hispanic or Latino             <ul> <li>A person of Mexican, Puerto Rican, Cuban, Central or South American or other Spanish culture or origin, regardless of race.</li> </ul> </li> <li>Not Evaluated         <ul> <li>Not provided or available.</li> <li>Unknown</li></ul></li></ul> | Provide the patient's ethnicity using the defined categories. 2192217  |
| 14 | Vessel Used  | ☐ Cryovial ☐ Cassette ☐ Other, specify ☐ Biospecimen Storage Bag ☐ Cryomold  | Indicate the type of vessel used to ship the tissue to the Biospecimen Core Resource (BCR) for TCGA.  3081940  |
| 15 | Other Vessel Used  |  | If the vessel used to ship the tissue to the BCR is not included in the provided list, specify the vessel used. 3288137  |
| 16 | Is tumor sample being submitted for Laser Cryo-Enrichment (LCE)? | □ Yes<br>□ No  | Indicate whether the tumor sample submitted to the BCR is intended to undergo Laser Cryo-Enrichment (LCE) after the BCR receives the sample.  3288488  |
| 17 | Was sample prescreened at site?                                  | □ Yes<br>□ No  | Indicate whether the sample submitted to the BCR was prescreened at the TSS. 3081942   |
| 18 | Will top slide be submitted to the BCR?                          | □ Yes<br>□ No  | Indicate whether a physical top slide for the sample submitted to the BCR will be shipped with the tissue sample.  3081944  Top Slide Definition: Slide cut directly from frozen biospecimen = mirror image of inked surface |

| #         | Question   | Entry Alternatives   | Working Instructions   |
|-----------|--|--|--|
| 19        | Will digital top slide image be sent to the BCR?     | □ Yes<br>□ No  | Indicate whether a digital slide image for the sample submitted to the BCR will be shipped with the tissue sample.  3081948 Physical top-slides are preferred.   |
| 20        | Will FFPE slide or image be submitted to the BCR?    | □ Slide □ Image  | Indicate whether a physical slide or digital slide image of the formalin-fixed paraffin-embedded (FFPE) diagnostic block will be shipped with the tissue sample to the BCR. 3295811  If the FFPE slide(s) or image(s) are sent in a shipment subsequent to the initial submission of tumor and normal samples, these questions can be skipped. |
| 21        | FFPE Slide/Digital Image<br>ID#                      |  | Provide the slide ID for the physical FFPE slide OR the FFPE digital slide image being sent to the BCR. 3295810  |
| Tumo      | or Information If the TSS is s                       | submitting multiple pieces of the same primary tumor for this case; complete the followin  | g information for each piece of tumor sent to the BCR.   |
| 22        | Tumor Identifier                                     |  | Provide the TSS unique tumor ID. If multiple pieces of tumor are submitted, each tumor needs a unique ID. 3288096  |
| 23        | Weight of Frozen Tumor                               | (mg) (0.2cm³ (0.6cm * 0.6cm * 0.6cm) = ~200mg  | Provide the weight of the tumor sample submitted for TCGA. 3081946   |
| 24        | Tumor Nuclei %                                       | (%)  | Provide the percent of tumor nuclei for the sample submitted for TCGA.  2841225 Check with the BCR to confirm the current acceptable TCGA metrics.   |
| 25        | Necrosis %   | (%)  | Provide the percent of necrosis for the sample submitted for TCGA. <u>2841237</u> Check with the BCR to confirm the current acceptable TCGA metrics.   |
| 26        | Slide/Digital Image ID #                             |  | Provide the slide ID for the physical top slide OR the digital slide image being sent to the BCR. 2321277  |
| Norm      | al Information A normal co                           | ntrol must be present to qualify.  |  |
| 25        | Type(s) of Normal<br>Control<br>Check all that apply | ☐ Whole Blood ☐ Buffy Coat ☐ Non-Neoplastic Control Tissue*  | Indicate the type of normal control submitted for this case.  3081936  *Non-neoplastic Control Tissue may only be submitted with NCI approval.   |
| Norr      | nal Control: Whole Blood                             |  |  |
| <u>26</u> | Method of Normal<br>Sample Procurement               | □ Blood Draw   | Indicate the procedure performed to obtain the normal control sample submitted for TCGA.  3288147  |
| <u>27</u> | Month of Normal Sample<br>Procurement                | 01         02         03         04         05         06         07         08         09         10         11         12  | Provide the month of the procedure performed to obtain the normal control submitted for TCGA.  3288195   |
| <u>28</u> | Day of Normal Sample<br>Procurement                  | 01       02       03       04       05       06       07       08       09       10       11       12         13       14       15       16       17       18       19       20       21       22       23       24         25       26       27       28       29       30       31 | Provide the day of the procedure performed to obtain the normal control submitted for TCGA.  3288196   |
| <u>29</u> | Year of Normal Sample<br>Procurement                 |  | Provide the year of the procedure performed to obtain the normal control submitted for TCGA. 3288197   |

| #         | Question                               | Entry Alternatives   | Working Instructions   |
|-----------|--|--|--|
| 30        | Normal Identifier                      |  | Provide the TSS unique normal ID. If multiple normal control samples are submitted, each normal control needs a unique ID. 3288138 |
| Norr      | nal Control: Buffy Coat/ Lyr           | nphocytes  |  |
| <u>31</u> | Normal Control Type                    | ☐ Buffy Coat ☐ Lymphocytes   | Indicate the type of normal control submitted for TCGA. 3081936  |
| <u>32</u> | Method of Normal<br>Sample Procurement | □ Blood Draw   | Indicate the procedure performed to obtain the normal control sample submitted for TCGA. $\underline{3288147}$                     |
| 33        | Month of Normal Sample<br>Procurement  | □ 01 □ 02 □ 03 □ 04 □ 05 □ 06 □ 07 □ 08 □ 09 □ 10 □ 11 □ 12  | Provide the month of the procedure performed to obtain the normal control submitted for TCGA.  3288195                             |
| 34        | Day of Normal Sample<br>Procurement    | 01       02       03       04       05       06       07       08       09       10       11       12         13       14       15       16       17       18       19       20       21       22       23       24         25       26       27       28       29       30       31 | Provide the day of the procedure performed to obtain the normal control submitted for TCGA.  3288196                               |
| <u>35</u> | Year of Normal Sample<br>Procurement   |  | Provide the year of the procedure performed to obtain the normal control submitted for TCGA.  3288197                              |
| <u>36</u> | Normal Identifier                      |  | Provide the TSS unique normal ID. If multiple normal control samples are submitted, each normal control needs a unique ID. 3288138 |
| Norr      | nal Control: Extracted DNA             | from Blood   |  |
| <u>37</u> | Method of Normal<br>Sample Procurement | □ Blood Draw   | Indicate the procedure performed to obtain the normal control sample submitted for TCGA.  3288147                                  |
| <u>38</u> | Month of Normal Sample<br>Procurement  | 01     02     03     04     05     06     07     08     09     01     01     01  | Provide the month of the procedure performed to obtain the normal control submitted for TCGA.  3288195                             |
| <u>39</u> | Day of Normal Sample<br>Procurement    | 01       02       03       04       05       06       07       08       09       10       11       12         13       14       15       16       17       18       19       20       21       22       23       24         25       26       27       28       29       30       31 | Provide the day of the procedure performed to obtain the normal control submitted for TCGA.  3288196                               |
| 40        | Year of Normal Sample<br>Procurement   |  | Provide the year of the procedure performed to obtain the normal control submitted for TCGA.  3288197                              |
| 41        | Normal Identifier                      |  | Provide the TSS unique normal ID. If multiple normal control samples are submitted, each normal control needs a unique ID. 3288138 |
| 42        | Extracted DNA Quantity                 | (μg)   | Provide the quantity (µg) of the normal control sample sent to the BCR for TCGA. $\underline{3288185}$                             |
| 43        | Extracted DNA<br>Quantification Method |  | Provide the quantification method of the normal control sample sent to the BCR for TCGA. 3288186                                   |
| <u>44</u> | Extracted DNA                          | (μg/μL)  | Provide the concentration (µg/ µL) of the normal control   |

| #         | Question   | Entry Alternatives   | Working Instructions  |
|-----------|--|--|---|
|           | Concentration                                      |  | sample sent to the BCR for TCGA.  3288187   |
| <u>45</u> | Extracted DNA Volume                               | (μL)   | Provide the volume ( $\mu L$ ) of the normal control sample sent to the BCR for TCGA.<br>3288188  |
| Norn      | nal Control: Non-Neoplastic                        | Control Tissue   |   |
| <u>46</u> | Method of Normal<br>Sample Procurement             | □ Surgical Resection □ Incisional Biopsy □ Other Method (please specify)   | Indicate the procedure performed to obtain the normal control sample submitted for TCGA.  3288147   |
| <u>47</u> | Other Method of Normal<br>Sample Procurement       |  | If the procedure performed to obtain the normal sample is not included in the provided list, specify the procedure. 3288151   |
| 48        | Month of Normal Sample<br>Procurement              | □ 01         □ 02         □ 03         □ 04         □ 05         □ 06         □ 07         □ 08         □ 09         □ 10         □ 11         □ 12  | Provide the month of the procedure performed to obtain the normal control submitted for TCGA.  3288195  |
| <u>49</u> | Day of Normal Sample                               | 01       02       03       04       05       06       07       08       09       10       11       12         13       14       15       16       17       18       19       20       21       22       23       24         25       26       27       28       29       30       31 | Provide the day of the procedure performed to obtain the normal control submitted for TCGA.  3288196  |
| <u>50</u> | Year of Normal Sample<br>Procurement               |  | Provide the year of the procedure performed to obtain the normal control submitted for TCGA.  3288197   |
| <u>51</u> | Normal Identifier                                  |  | Provide the TSS unique normal ID. If multiple normal control samples are submitted, each normal control needs a unique ID. 3288138  |
| <u>52</u> | Anatomic Site of Non-<br>Neoplastic Control Tissue | ☐ Thyroid ☐ Left ☐ Right ☐ Other, (please specify)   | If the normal control type is normal tissue, indicate the anatomic site of the non-neoplastic control tissue submitted for TCGA.  3081938 Site matched is preferred.  If non-neoplastic control tissue FROM THYROID is submitted it   |
| <u>53</u> | Other Site of Non-<br>Neoplastic Control Tissue    |  | must be from the lobe uninvolved by cancer.  If the normal control type is normal tissue and the anatomic site is not included in the provided list, specify the site of the non-neoplastic control.  3288189   |
| <u>54</u> | Proximity of Normal<br>Tissue to Tumor             | ☐ Distal (> 2cm) from the primary tumor  | If the normal control type is normal tissue, confirm that the submitted normal tissue was at least 2cm away from the primary tumor.  3088708  Adjacent (≤ 2cm) Normal Tissue is not accepted for this tissue type.  Unknown Normal Tissue is not acceptable for this tissue type. |
| <u>55</u> | Normal Slide ID#                                   |  | If the normal control type is normal tissue, provide the slide ID for the physical top slide OR the digital slide image of the normal control being sent to the BCR.  3288217   |

|               |   | Thyroid (Trich)           |  |  |  |  |  |  |  |  |
|---------------|---|---------------------------|--|--|--|--|--|--|--|--|
| #             | Question  | Entry Alternatives        | Working Instructions   |  |  |  |  |  |  |  |
|               | erification: By providing the below information, the Principal Investigator acknowledges that the information provided by the institution is true and correct and has been uality controlled.   |                           |  |  |  |  |  |  |  |  |
| Tissu<br>repo | Pathology Review Tissue Source Site (TSS) acknowledges that the Biospecimen Core Resource (BCR) may confirm that the diagnosis of the frozen biospecimen is consistent with the primary diagnosis eported by the TSS through histopathology examination in the BCR laboratory. If the BCR identifies a possible discrepancy, the TSS authorizes the BCR to report these patient esults to the TSS by means of a formal report in confidential email format for the quality assurance program of the TSS to address. |                           |  |  |  |  |  |  |  |  |
| 56            | Name of Pathologist   |                           | Provide the name of the Pathologist that provided the information for all previous sections.  3288225  |  |  |  |  |  |  |  |
| 57            | Date of Pathologist<br>Review   |                           | Provide the date of the pathology review performed by the TSS pathologist above. 3288224   |  |  |  |  |  |  |  |
| Prin          | cipal Investigator/Authoriz   | zed Designee Confirmation | ,  |  |  |  |  |  |  |  |
| 58            | Percent Tumor Nuclei<br>meets TCGA metrics?   | □ Yes<br>□ No             | Confirm that the malignant sample submitted to the BCR meets the current tumor nuclei metrics for TCGA.  3288520 Check with the BCR to confirm the current acceptable TCGA metrics.  |  |  |  |  |  |  |  |
| 59            | Percent Necrosis meets TCGA metrics?  | □ Yes<br>□ No             | Confirm that the malignant sample submitted to the BCR meets the current necrosis metrics for TCGA.  3288524 Check with the BCR to confirm the current acceptable TCGA metrics.  |  |  |  |  |  |  |  |
| 60            | De-Identified Pathology<br>Report Submitted?  | □ Yes<br>□ No             | Confirm that a de-identified pathology report will be sent to BCR prior to or with the shipment of the physical samples.  3288292  |  |  |  |  |  |  |  |
| 61            | Is the histologic diagnosis on the CQCF (as determined by the TSS pathology review of the TCGA frozen section top slide) consistent with the histology listed in the final diagnosis on the pathology report?   | □ Yes □ No                | Confirm that the diagnosis provided on this CQCF for the tumor sample being submitted to TCGA is consistent with the diagnosis found on the patient's pathology report for the tumor being sent to the BCR.  3288300  If "yes," skip related question below. The diagnosis is considered to be consistent if at least one of the following criteria are met:  1) Diagnosis on the CQCF is identical to the pathology report for the tumor being sent to the BCR.  2) Diagnosis on the CQCF includes as least one of the subtypes listed on the pathology report and all subtypes on the pathology report are acceptable for TCGA.  3) Diagnosis on the CQCF is "histology, NOS" (i.e., Adenocarcinoma, NOS) and the pathology report lists a specific subtype within the same histologic group.  4) Diagnosis on the CQCF indicates "Mixed Subtype" and the pathology report lists two or more acceptable subtypes, provided that percent subtype(s) meet applicable TCGA disease-specific requirements. |  |  |  |  |  |  |  |

|      | Thyroid (TheA)   |  |  |  |  |  |  |  |  |
|------|--|--|--|--|--|--|--|--|--|
| #    | Question   | Entry Alternatives   | Working Instructions   |  |  |  |  |  |  |
| 62   | If the diagnosis on this form is not consistent with the provided pathology report, indicate the reason for the inconsistency. | □ Macrodissection performed at TSS to select for a region containing an acceptable         TCGA diagnosis (see note at right) □ Pathology analysis at TSS determined a specific histological subtype different from original pathology report (see note at right) □ Pathology review of frozen section for TCGA determined histological subtype different from the pathology report (see note at right) □ Pathology review of frozen section for TCGA determined histological subtype different from the pathology report (see note at right) □ Pathology review of frozen section for TCGA determined histological subtype different from the pathology report (see note at right) □ Pathology review of frozen section for TCGA determined histological subtype different from the pathology report (see note at right) □ Pathology review of frozen section for TCGA determined histological subtype different from the pathology report (see note at right) □ Pathology review of frozen section for TCGA determined histological subtype different from the pathology report (see note at right) □ Pathology review of frozen section for TCGA determined histological subtype different from the pathology report (see note at right) □ Pathology review of frozen section for TCGA determined histological subtype different from the pathology report (see note at right) □ Pathology review of frozen section for TCGA determined histological subtype different from the pathology report (see note at right) □ Pathology review of frozen section for TCGA determined histological subtype different from the pathology report (see note at right) □ Pathology review of frozen section for TCGA determined histological subtype different from the pathology report (see note at right) □ Pathology review of frozen section for TCGA determined histological subtype different from the pathology report (see note at right) □ Pathology review of frozen section for TCGA determined histological subtype different from the diagnosis found on the pathology report preason for this inconsistency. |  |  |  |  |  |  |  |
| 63   | History of Other<br>Malignancy   | □ None □ History of Prior Malignancy □ History of Synchronous/ Bilateral Malignancy  | modifications, institution protocol should be followed for proper quality assurance.  Indicate whether the patient has a history of malignancies. If the patient has any history, including synchronous or bilateral malignancies, please complete an "Other Malignancy Form" for each malignancy diagnosed prior to the procurement of the tissue submitted for TCGA.  3382736  If the patient has a history of multiple diagnoses of basal or squamous cell skin cancer, only complete an OMF for the first diagnosis for each of these types. |  |  |  |  |  |  |
| 64   | History of Neoadjuvant<br>Treatment <i>for Tumor</i><br><i>Submitted for TCGA</i>  | □ None □ Radiation prior to sample procurement* □ Pharmaceutical treatment prior to sample procurement* □ Both pharmaceutical treatment and radiation prior to sample procurement*   | Indicate whether the patient received therapy for this cancer prior to the sample procurement of <i>the tumor submitted for TCGA</i> . If the patient did receive treatment for this cancer prior to procurement, the TSS should contact the BCR for further instruction.  3382737  *Systemic therapy and certain localized therapies (those administered to the same site as the TCGA submitted tissue) given prior to the procurement of the sample submitted for TCGA are exclusionary.   |  |  |  |  |  |  |
| 65   | Consent Status   | ☐ Consented ☐ Exemption 4* ☐ Deceased ☐ Waiver*  | Indicate whether the patient was formally consented, consented by death, or if the case has an exemption or waiver for consent. 3288361  *Exemptions and waivers for consent must be approved by NCI.  |  |  |  |  |  |  |
| Date | of Formal Consent  |  |  |  |  |  |  |  |  |
| 66   | Month of Consent   |  | If the patient was formally consented, provide the month of consent. 3081955   |  |  |  |  |  |  |
| 67   | Day of Consent   | $ \begin{array}{c ccccccccccccccccccccccccccccccccccc$   | If the patient was formally consented, provide the day of consent. 3081957   |  |  |  |  |  |  |
| 68   | Year of Consent  |  | If the patient was formally consented, provide the year of consent. 3081959  |  |  |  |  |  |  |

| Page 8 | Initial Case Quality Control Form | V4.05 091112 |
|--------|-----------------------------------|--------------|
|        | Thyroid (THCA)                    |              |

| #  | Question  |                      | Entry Alternatives   |                      |                      |                      |                      |                      |              |              | Working Instructions |              |              |   |
|--|---|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|--------------|--------------|----------------------|--------------|--------------|---|
| Date   | Date of Death Do not complete date of death, if patient formally consented. |                      |                      |                      |                      |                      |                      |                      |              |              |                      |              |              |   |
| 69   | Month of Death  | <b>1</b> 01          | <b>1</b> 02          | <b>1</b> 03          | <b>1</b> 04          | <b>1</b> 05          | <b>1</b> 06          | <b>1</b> 07          | □ 08         | <b>1</b> 09  | <b>1</b> 0           | <b>1</b> 1   | <b>1</b> 2   | If the patient consented by death, provide the month of death. $\underline{\textbf{2897026}}$ |
| 70   | Day of Death  | □ 01<br>□ 13<br>□ 25 | □ 02<br>□ 14<br>□ 26 | □ 03<br>□ 15<br>□ 27 | □ 04<br>□ 16<br>□ 28 | □ 05<br>□ 17<br>□ 29 | □ 06<br>□ 18<br>□ 30 | □ 07<br>□ 19<br>□ 31 | □ 08<br>□ 20 | □ 09<br>□ 21 | □ 10<br>□ 22         | □ 11<br>□ 23 | □ 12<br>□ 24 | If the patient consented by death, provide the day of death. 2897028                          |
| 71   | Year of Death   |                      |                      |                      |                      |                      |                      |                      |              |              |                      |              |              | If the patient consented by death, provide the year of death.<br>2897030                      |
| Principal Investigator or Designee Signature |   |                      |                      |                      |                      |                      |                      | <br>Prir             | nt Name      |              |                      |              | / /<br>Date  |   |

I acknowledge that the above information provided by my institution is true and correct and has been quality controlled.

#### Page 9

### Initial Case Quality Control Form Thyroid (THCA)

**Time Intervals:** The following questions are only to be answered if the Tissue Source Site is unable to provide the dates requested on this form.

| #    | Question  | Entry Al                          | ternatives | Working Instructions   |
|------|---|-----------------------------------|------------|--|
| i.   | Number of Days from<br>Date of Diagnosis to Date<br>of Cancer Sample<br>Procurement |                                   | days       | Provide the number of days from the date the patient was diagnosed with the disease described on this form to the date of the procedure that produced the malignant sample submitted for TCGA.  328495   |
| ii.  | Number of Days from<br>Date of Diagnosis to<br>Normal Sample<br>Procurement         |                                   | days       | Provide the number of days from the date the patient was diagnosed with the disease described on this form to the date of the procedure that produced the normal control sample submitted for TCGA.  3288496   |
| iii. | Number of Days from<br>Date of Diagnosis to Date<br>of Pathological Review          |                                   | days       | Provide the number of days from the date the patient was diagnosed with the disease described on this form to the date of the pathological review performed as part of the submission process for TCGA.  3288497   |
| iv.  | Number of Days from<br>Date of Diagnosis to Date<br>of Consent                      |                                   | days       | If the patient formally consented, provide the number of days from the date the patient was diagnosed with the disease described on this form to the date of the patient's formal consent.  3288498  |
| v.   | Number of Days from<br>Date of Diagnosis to Date<br>of Death                        |                                   | days       | If the patient consented by death, provide the number of days from the date the patient was diagnosed with the disease described on this form to the date of the patient's death.  328499  Do not complete days to death, if patient formally consented. |
|      |   |                                   |            | /  |
|      | Principal In  | nvestigator or Designee Signature | Print Name | Date   |

I acknowledge that the above information provided by my institution is true and correct and has been quality controlled.